Stifel Reiterates Buy on Relay Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has reiterated a Buy rating on Relay Therapeutics (NASDAQ:RLAY) and maintained a price target of $28.
September 16, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino has reiterated a Buy rating on Relay Therapeutics and maintained a price target of $28, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $28 price target by a reputable analyst suggests positive sentiment and confidence in Relay Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100